Pomalidomide (INN originally CC-4047 or 3-amino-thalidomide trade name Pomalyst in the US) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator. Pomalidomide was approved in February 2013 by the U.S. Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma.
This page contains content from the copyrighted Wikipedia article "Pomalidomide"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
